Merck/Sanofi Pasteur (MSP)

Home
/
Partners & Products
/
Vaccines
/
Merck/Sanofi Pasteur (MSP)

Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available! Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.

The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component. For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppmnull@ofni.

MPPG Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.

More details about Vaxelis™ may be found at website www.vaxelis.com

Client Testimonials

"Our savings on our malpractice insurance alone were significant. I highly recommend MPPG."

"MPPG has proven to be very beneficial to our practice's bottom line."

"Our practice has been a member of MPPG now since 2009 and we couldn’t be happier!"

"In order for private practice pediatricians to survive these difficult times we need programs like MPPG to help us lower our overhead."

"I have been a member of MPPG for over a decade and have enjoyed saving thousands of dollars on my vaccine purchases and vendors."

"We could not be more happy with Brian Greenberg, M.D. and MPPG."

"We even get a sizable rebate at the end of the year."

"When I first heard about MPPG, I thought it was too good to be true. The vaccine savings are significant!"

Merck/Sanofi Pasteur (MSP)

Client Testimonials

Subscribe for Email Updates

Latest News

News Archives